India, July 16 -- Clearmind Medicine Inc. (CMND), a clinical-stage biotechnology company, on Thursday released ex vivo data for an intranasal MEAI formulation indicating improved retention compared to standard formulae.
The intranasal formulation of 5-methoxy-2-aminodindane (MEAI) has been developed by the company drugs for the treatment of alcohol use disorder (AUD), addiction, and weight loss management. The drug is an investigational, MEAI-based non-hallucinogenic neuroplastogen designed as a mucoadhesive to bind to nasal tissue.
In the ex vivo study, freshly isolated rabbit mucosal tissue was exposed to the company's proprietary MEAI formulation and a standard, non-mucoadhesive MEAI formulation. The amount of formulation retained on t...